
What to do when your grant application fails
All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
Newsletters and Deep Dive digital magazine
All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.
Editor's Picks
Newsletters and Deep Dive
digital magazine